Drug Trial Radar · NCT07059000
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Aug 13, 2025
Primary completion
Dec 2026
Study completion Jan 2027
Sponsor
- Lead sponsor
- Kedrion S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Jul 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult patients with chronic primary ITP
Conditions
- Chronic Primary Immune Thrombocytopenia (ITP)
Interventions
Kedrion IVIG 10%Biological
(Intravenous) Human Normal Immunoglobulin (IVIg) 10%
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of subjects with response (R)Time frame: Treatment to day 14
Locations
28 sites in 8 countries. Site status is shown where the registry gives one.
University of Southern California
Los Angeles, California · Recruiting
NY Cancer and Blood Specialists
Shirley, New York · Recruiting
East Carolina University
Greenville, North Carolina · Recruiting
Vseobecna Fakultni Nemocnice v Praze
Prague, Prague, Czechia · Recruiting
Fakultni Nemocnice Brno
Brno, South Moravian, Czechia · Recruiting
Onkologisches Zentrum Donauwörth Neudegger - Onkomedeor Onkologische Zentren
Donauwörth, Bavaria, Germany · Withdrawn
Universitätsklinikum Frankfurt
Frankfurt am Main, Hesse, Germany · Recruiting
Azienda Ospedaliero - Universitaria Careggi
Florence, Florence, Italy · Recruiting
Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara
Novara, Novara, Italy · Recruiting
Azienda Sanitaria Universitaria Giuliano Isontina
Trieste, Trieste, Italy · Recruiting
Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino
Torino, Turin, Italy · Recruiting
AULSS 8 Berica - Ospedale San Bortolo Di Vicenza
Vicenza, Vicenza, Italy · Recruiting
Coltea - Spital Clinic
Bucharest, Bucharest, Romania · Recruiting
Institutul Oncologic Prof. Dr. Ion Chiricuta
Cluj-Napoca, Cluj, Romania · Recruiting
Spitalul Filantropia - Craiova
Craiova, Dolj, Romania · Recruiting
Univerzitetski Klinicki Centar Srbije
Belgrade, Serbia · Recruiting
Klinicko-Bolnicki Centar Zemun
Belgrade, Serbia · Terminated
Complejo Asistencial Universitario de Burgos - Hospital Universitario de Burgos
Burgos, Burgos, Spain · Withdrawn
Instituto De Investigacion Biomedica De A Coruna - Virologia Clinica
A Coruña, La Coruña, Spain · Recruiting
Complejo Hospitalario Ruber Juan Bravo
Madrid, Madrid, Spain · Recruiting
Hospital General Universitario Gregorio Marañón
Madrid, Madrid, Spain · Recruiting
Ankara Üniversitesi Tip Fakültesi - Cebeci Arastirma ve Uygulama Hastanesi
Ankara, Ankara, Turkey (Türkiye) · Recruiting
Kocaeli Üniversitesi Arastirma ve Uygulama Hastanesi
Ankara, Ankara, Turkey (Türkiye) · Recruiting
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi
Yenimahalle, Ankara, Turkey (Türkiye) · Recruiting
Trakya Üniversitesi Saglik Arastirma ve Uygulama Merkezi
Edirne, Edirne, Turkey (Türkiye) · Recruiting
Ege Universitesi Tip Fakultesi
Izmir, İzmir, Turkey (Türkiye) · Recruiting
VM Medical Park Mersin Hastanesi
Mersin, Mersin, Turkey (Türkiye) · Recruiting
Sakarya Universitesi Egitim ve Arastirma Hastanesi
Adapazarı, Sakarya, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.